Camber Pharmaceuticals is voluntarily recalling all unexpired lots of Valsartan tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level, as a precautionary measure.
This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N- Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).
NDMA is classified as a probable human carcinogen (a substance that could cause cancer), as per International Agency for Research on Cancer (IARC) classification. To date, Camber has not received any reports of adverse events related to this recall.
Valsartan Tablets, USP, is a prescription medication used to treat high blood pressure and congestive heart failure and is packaged in 30ct bottles & 90ct bottles, all associated codes are provided in the table below with lot # and expiration dates.
|Product Description||NDC Number||Batches||Exp. Date|
|Valsartan Tablets USP, 40mg||31722-745-30||All lots||07/2018 – 06/2020|
|Valsartan Tablets USP, 80mg||31722-746-90||All lots||07/2018 – 06/2020|
|Valsartan Tablets USP, 160mg||31722-747-90||All lots||07/2018 – 06/2020|
|Valsartan Tablets USP, 320mg||31722-748-90||All lots||07/2018 – 06/2020|
Valsartan Tablets were distributed Nationwide to Wholesalers, Distributors, Hospitals and Retail Pharmacies and Mail Order Pharmacies.
Qualanex, LLC will be notifying Camber’s distributors and other customers by recall letter and arranging for return of all recalled products.
Consumers should contact their doctor for further guidance and potential change of treatment before they stop taking this product. Pharmacies and healthcare facilities that have product being recalled should stop using and dispensing the product immediately.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Source: Company Press Release.